stockrow
Friday 6 November 2026
Export GOSS’s income statement to Excel — free account
Gossamer Bio, Inc.
GOSS Healthcare Biotechnology
Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024.
- Revenue
- −19.6%
- EPS
- +129.4%
- Free cash flow
- +16.3%
- Total debt
- −81.7%
Quarter to June 2026, against a year earlier
9.75
0.33
+3.50%
Follow GOSS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.99 | 1.38 | 14.62 | 13.61 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.34) | (1.99) | (14.66) | (16.58) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.33 | 3.35 | 16.08 | 14.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.42) | (1.09) | (4.55) | (3.96) | |
EV/FCF |
(1.42) | (1.09) | (4.55) | (3.95) | |
Quick Ratio |
0.46 | 1.92 | 2.35 | 3.05 | |
Current Ratio |
0.53 | 2.20 | 2.64 | 3.28 | |
Net Debt/EBITDA |
0.98 | (2.21) | (1.32) | (0.36) | |
Debt/Assets |
47.02% | 154.20% | 115.24% | 94.94% | |
Debt/Equity |
(0.38) | (1.23) | (1.62) | (2.41) | |
Asset Turnover |
0.34 | 0.27 | 0.20 | 0.16 | |
Operating CF/Net income |
(2.33) | 0.83 | 1.02 | 0.75 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(9.64) | (16.29) | (16.74) | (17.87) | |
Research and Development Expense of Revenue |
285.91% | 254.05% | 354.63% | 342.58% | |
Selling, General and Administrative Expense of Revenue |
96.34% | 110.56% | 79.02% | 70.63% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
26.66% | 37.18% | 21.00% | 20.05% | |
Graham Net Nets |
(1.86) | (2.16) | (0.18) | (0.15) | |
Graham Number |
155.30 | 280.11 | 240.87 | 189.43 | |
Earnings Yield |
(346.24%) | (240.49%) | (24.19%) | (26.24%) | |
Free Cash Flow Yield |
(308.84%) | (221.47%) | (24.19%) | (26.45%) | |
Revenue per Share |
2.31 | 5.79 | 4.83 | 4.66 | |
Operating CF per Share |
(9.86) | (13.23) | (16.91) | (12.69) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(9.86) | (13.23) | (16.91) | (12.69) | |
Cash per Share |
14.26 | 33.90 | 47.94 | 63.24 | |
Shareholders Equity per Share |
(23.51) | (55.18) | (42.98) | (28.89) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(23.51) | (55.18) | (42.98) | (28.89) | |
Free Cash Flow |
(39.42) | (38.72) | (48.31) | (36.17) | |
Working Capital |
(65.06) | 68.03 | 104.21 | 141.87 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
(98.17) | (165.85) | (127.36) | (87.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.84 | 7.92 | 8.78 | 7.92 | |
Average Payables |
3.91 | 7.11 | 4.14 | 2.09 | |
Average Assets |
158.90 | 204.74 | 243.77 | 279.85 | |
Average Common Equity |
(70.07) | (83.87) | (46.63) | (14.10) |
Columns are period end dates · fundamentals updated 26 Oct 2026